Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Preeclampsia and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LGALS13 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LGALS13 ECD-Fc / Recombinant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed to preserve native disulfide-linked homodimerization. |
View LGALS13 Products |
| Gene Delivery | LGALS13 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression validation. |
View LGALS13 Products |
| Benchmark Ab | Anti-LGALS13 Recombinant Antibody High-affinity positive control for ELISA, Western Blot, and functional blocking assays. |
View LGALS13 Products |
| Validator | LGALS13 siRNA Set Target-specific knockdown pool for functional loss-of-function verification. |
View LGALS13 Products |
| Related Target A | PGF (Placental Growth Factor) Synergistic biomarker with LGALS13 in preeclampsia screening and maternal-fetal vascular development. |
View PGF Products |
| Related Target B | FLT1 (sFlt-1 / VEGFR1) Soluble Fms-like tyrosine kinase-1, a key antagonist in the preeclampsia angiogenic pathway. |
View FLT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homodimerization Preservation | HEK293 mammalian expression system ensures correct folding and disulfide-bond mediated dimerization required for lectin activity. |
| Cross-species Epitope Screening | Human, Cynomolgus, and Rodent ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available as reference standards. |
| Off-Target Lectin Cross-Reactivity | Galectin family counter-screening panel (LGALS1, LGALS3, LGALS9) for selectivity profiling. |
Live LGALS13 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LGALS13 therapeutics is intensifying, with major players shifting focus from traditional diagnostics to recombinant protein supplementation and targeted immunotherapies. As first-generation diagnostic biomarkers for preeclampsia reach clinical maturity, the next wave of R&D is targeting maternal-fetal immune tolerance and vascular remodeling pathways. Recombinant LGALS13 (Placental Protein 13) is under investigation as a therapeutic agent to prevent placental insufficiency by restoring normal uterine artery remodeling and maternal immune homeostasis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Protein | Academic Medical Centers, Maternal-Fetal Biotech | Early-onset Preeclampsia, Fetal Growth Restriction | Functional assay support (Need endotoxin-controlled, homodimeric LGALS13) |
| Monoclonal Antibodies | Oncology-focused Biopharma | Gynecological Cancers, Immune Evasion | Epitope mapping and binding kinetics (Need high-purity ECD-Fc proteins) |
| Diagnostic Kits (ELISA) | Roche Diagnostics, PerkinElmer, Thermo Fisher | First-trimester Prenatal Screening | High-affinity detection antibodies and highly stable calibrator antigens |